Norristown, PA, United States of America

G Mark Anderson

USPTO Granted Patents = 4 

Average Co-Inventor Count = 4.7

ph-index = 2

Forward Citations = 46(Granted Patents)


Location History:

  • Norristown, PA (US) (1996 - 2012)
  • Radnor, PA (US) (2017)

Company Filing History:


Years Active: 1996-2017

Loading Chart...
4 patents (USPTO):Explore Patents

Title: G Mark Anderson: Innovator in Anti-Tissue Factor Antibodies

Introduction

G Mark Anderson is a notable inventor based in Norristown, PA (US), recognized for his contributions to the field of biotechnology. He holds a total of four patents, focusing primarily on anti-tissue factor antibodies and their applications in medical treatments.

Latest Patents

Anderson's latest patents include innovative developments in isolated anti-tissue factor antibodies, immunoglobulins, and their variants that exhibit enhanced antibody-dependent cellular cytotoxicity (ADCC) activity. These antibodies are designed to bind human tissue factor, making them valuable in diagnosing, treating, and preventing diseases where enhanced ADCC activity is beneficial, such as cancer. His work encompasses a range of compositions, formulations, devices, and methods related to these antibodies.

Career Highlights

Throughout his career, G Mark Anderson has worked with prominent companies in the biotechnology sector, including Centocor, Inc. and Magainin Pharmaceuticals, Inc. His expertise in the field has led to significant advancements in therapeutic applications of antibodies.

Collaborations

Anderson has collaborated with notable professionals in his field, including Bernard Scallon and Michael Naso, contributing to the development of innovative solutions in biotechnology.

Conclusion

G Mark Anderson's work in anti-tissue factor antibodies represents a significant advancement in medical science, particularly in cancer treatment. His patents and collaborations highlight his impact on the biotechnology industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…